Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Caplin Point Laboratories Limited

Market Cap 177B 1.85B 1.61B 1.48B 1.39B 2.59B 2.65B 17.66B 6.84B 85.4B 6.95B 6.8B 297B P/E Ratio 2026
17.9x
P/E Ratio 2027 * 24.8x
Enterprise Value 177B 1.85B 1.61B 1.48B 1.39B 2.59B 2.65B 17.66B 6.84B 85.4B 6.95B 6.8B 297B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.12x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.17%
1 day+2.56%
1 week+17.58%
Current month+18.08%
1 month+31.71%
3 months+41.66%
6 months+21.73%
Current year+30.06%
1 week 2,001.5
Extreme 2001.5
2,425
1 month 1,803
Extreme 1803
2,425
Current year 1,500.3
Extreme 1500.3
2,425
1 year 1,500.3
Extreme 1500.3
2,425
3 years 781.85
Extreme 781.85
2,641
5 years 575
Extreme 575
2,641
10 years 176.2
Extreme 176.2
2,641
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
+2.58%+17.58% - - 1.85B
+0.73%+1.46%+7.16%+83.50% 44.96B
-0.20%-3.59%+38.01%+87.26% 33.53B
+0.68%-0.57%-7.29%+45.14% 11.67B
-0.20%+1.39%+12.80%+116.49% 11.62B
+1.36%+0.78%+37.07%+126.43% 8.97B
+2.58%+0.25%+17.97%+43.46% 6.89B
-1.12%-0.56%+40.12%-18.60% 6.55B
+0.59%-0.42%+31.56%+237.80% 6.32B
-0.45%-2.96%-39.97%-6.82% 5.12B
Average +0.60%-0.88%+15.27%+79.41% 15.07B
Weighted average by Cap. +0.43%-1.10%+17.50%+83.61%

Financials

2026 2027 *
Net sales 21.28B 222M 193M 178M 167M 311M 318M 2.12B 821M 10.26B 834M 816M 35.66B 24.88B 260M 225M 208M 195M 364M 371M 2.48B 960M 11.99B 975M 954M 41.7B
Net income 6.16B 64.35M 55.85M 51.48M 48.24M 90.12M 92M 614M 238M 2.97B 242M 236M 10.33B 7.13B 74.44M 64.6M 59.54M 55.79M 104M 106M 710M 275M 3.44B 279M 273M 11.95B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
26-06-12 2,391.20 +2.58% 151,308
26-06-11 2,331.00 +0.94% 286,180
26-06-10 2,309.40 +2.40% 861,544
26-06-09 2,255.20 +6.83% 614,724
26-06-08 2,111.00 +3.83% 628,306
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,330.80INR
Average target price
2,505.00INR
Spread / Average Target
+7.47%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!